Figure 5.
Neutralization breath and potency of CAP256.J3LS antibody. (a) Neutralization IC80 of CAP256.J3LS on a 208 global virus panel in comparison with parental antibodies and select HIV-1 antibodies in clinical development. (b) Neutralization IC80 of CAP256.J3LS on a 100 Acute-Early Clade C virus panel. (c) Breadth-IC80 curves of CAP256.J3LS in comparison with parental antibodies and select HIV-1 antibodies in clinical development.